Renee
2 years ago
Ever seen the TV series The Walking Dead? Well, that's what happens to most OTC stocks that are not compliant with Amended Rule 15c2-11, ie., inadequate (or no) disclosures.
The exceptions are cult stocks like any of the George Sharp putrid stinkers that somehow hang on, and on, and on, in lieu of any common sense.
Renee
4 years ago
AVTI: As of May 25, 2021, TD Ameritrade will restrict orders in Caveat Emptor designated OTC securities to liquidating trades only.
A Caveat Emptor security is a designation the OTC Markets Group places on a security after a determination was made surrounding the company that there may be potential risk to investors which include a questionable stock promotion, known investigation of fraudulent activity committed by the company or insiders, regulatory suspensions, or disruptive corporate actions, among other reasons.
The current list of Caveat Emptor restricted securities is below as of April 12, 2021 and is subject to change at any time.
Please visit www.otcmarkets.com for additional details and real time Caveat Emptor desiginations.
https://www.tdameritrade.com/retail-en_us/resources/pdf/cesecuritylist.pdf
WarMachine
5 years ago
PUMP AND DUMP FRONT LOADING
The Caveat Emptor Designation may be assigned when OTC Markets becomes aware of one or more of the following:
•Promotion — The security is the subject of stock promotion that may be misleading or manipulative. Promotional activities may include news releases, spam email, and newsletters, whether they are published by the issuer or a third party. See OTC Markets Group's Policy on Stock Promotion.
•Investigation of Fraud or Other Criminal Activities — There is an investigation or other indication of fraudulent or other criminal activity involving the company, its securities or insiders.
•Suspension/Halt — A regulatory authority or an exchange has halted or suspended trading for public interest concerns (i.e. not a news or earnings halt).
•Undisclosed Corporate Actions — The security or company is the subject of a corporate action, such as a reverse merger, stock split, or name change, without adequate current information being publicly available.
•Other Public Interest Concern — OTC Markets Group may determine that there is a public interest concern regarding the security. Such concerns may include but are not limited to promotion campaigns (including third-party), unusual or unexplained trading activity, spam or disruptive corporate actions even when adequate current information is available.
MoreThanWealth
6 years ago
just last September he was tied to this
Detail by Officer/Registered Agent Name
Florida Profit Corporation
PREMIER MEDICAL GROUP, INC.
Filing Information
Document Number
P93000051019
FEI/EIN Number
65-0423029
Date Filed
07/16/1993
State
FL
Status
INACTIVE
Last Event
ADMIN DISSOLUTION FOR ANNUAL REPORT
Event Date Filed
09/28/2018
Event Effective Date
NONE
Principal Address
1800 N.W. CORPORATE BLVD., STE 201
BOCA RATON, FL 33431
Changed: 08/05/2010
Mailing Address
1800 N.W. CORPORATE BLVD., STE 201
BOCA RATON, FL 33431
Changed: 08/05/2010
Registered Agent Name & Address
Corporate Creations Network Inc.
11380 Prosperity Farms Road
#221E
Palm Beach Gardens, FL 33410
Name Changed: 04/14/2016
Address Changed: 04/14/2016
Officer/Director Detail
Name & Address
Title MR
GELMON, CORY
1800 N.W. CORPORATE BLVD., STE 201
BOCA RATON, FL 33431
MoreThanWealth
6 years ago
how is this still even trading tho?
ALBERTA SECURITIES COMMISSION - CEASE TRADE ORDER
Announcement | 10/20/2014
ALBERTA SECURITIES COMMISSION
CEASE TRADE ORDER
Citation: Re Avitar, Inc., 2014 ABASC 405 Date: 20141020
Avitar, Inc.
Background
1. Avitar, Inc. (the Issuer) is an OTC reporting issuer under Multilateral Instrument 51-105 Issuers Quoted in the U.S. Over-the-Counter Markets and has been an OTC reporting issuer since at least July 31, 2012.
2. The Issuer has failed to file any of the periodic disclosure required under section 146 of the Securities Act (Alberta) (the Act) since that date.
Decision
3. Under section 33.1 of the Act, it is ordered that trading or purchasing cease in respect of each security of the Issuer until this order has been revoked or varied.
20 October 2014
"original signed by"
Tom Graham, CA
Director, Corporate Finance
MoreThanWealth
6 years ago
Full Description
Avitar, Inc. (Avitar), through its wholly owned subsidiary Avitar Technologies, Inc. (ATI), develops, manufactures, markets and sells diagnostic test products and hydrophilic polyurethane foam disposables fabricated for medical, diagnostics, dental and consumer use. During the fiscal year ended September 30, 2007 (fiscal 2007), the Company continued the development and marketing of point-of-care oral fluid drugs of abuse tests, which use the Company’s foam as the means for collecting the oral fluid sample. Avitar sells its products and services to employers, diagnostic test distributors, medical supply companies, governmental agencies and corporations. Through its wholly owned subsidiary, BJR Security, Inc. (BJR), the Company provided, until April 30, 2007, specialized contraband detection and education services.
Diagnostic Test Products and Drug Detection Services
The Company makes products and offers services for the diagnostic test applications. These products accounted for approximately 60% of the Company's revenue in fiscal 2007. The Company’s ORALscreen 4 and ORALscreen DRUGOMETER are oral fluid-based, rapid onsite assay systems for detecting drugs of abuse, such as opiates (including heroin, morphine, codeine and synthetic opiates like Oxycocone-Oxycontin, Percoset and Hydrocodone-Vicodin), cocaine (including crack), marijuana and methamphetamines (including Meth and Ecstasy). These tests are performed onsite and yield accurate results in a 5-15 minute period of time. In addition, Avitar offers ORALconfirm, an oral fluid laboratory test to confirm the results of ORALscreen tests, ORALscreenLab, a range of laboratory-based oral fluid drug screening products, and various other services to enable an employer to manage and control its drug testing program.
Foam Disposable Products
Avitar's Hydrasorb (Hydrasorb) wound dressing product is an absorbent topical dressing for moderate to heavy exudating wounds. These dressings have a construction that provides a moist wound healing environment, which promotes skin growth and closure. The Hydrasorb product is marketed by the Dukal Corp., Abbott Laboratories, Ltd. and other specialty distributors worldwide. In addition to the Hydrasorb line, the Company has custom-developed specialty wound dressings for the cardiac catheter lab market, as well as the Illizarov Dressing used for dressing external bone fixators in orthopedic procedures. Customers for these products include Smith and Nephew and Cardinal Health.
The Company continues to have applications for its technologies in a variety of other medical/consumer markets. They include a sinus dressing and a device used by astronauts for relieving ear pressure while in a pressurized space suit. Customers for these products include ArthroCare and National Aeronautics and Space Administration (NASA).
Avitar competes with Bristol Meyers Squibb, Johnson & Johnson, Smith and Nephew, 3M, Acme United, Varian Instruments, American BioMedica Corp., OraSure Technologies, Inc., Novacon, Concateno, PLC, Branan and Securetec Detektions-Systeme, AG.
moolamoola
6 years ago
this dead ticker has updated SS...and transfer agent verified since June 17? is that new?
AVTI
Avitar, Inc.
Common Stock
Overview
Quote
Company Profile
Security Details
News
Financials
Disclosure
Research
AVTI SECURITY DETAILS
Share Structure
Market Cap Market Cap
292,526
06/17/2019
Authorized Shares
800,000,000
06/17/2019
Outstanding Shares
731,314,846
06/17/2019
Restricted
427,944
06/17/2019
Unrestricted
730,886,902
06/17/2019
Held at DTC
729,294,826
06/17/2019
Float
700,000,000
08/17/2010